Advanced Filters
noise

Pain Clinical Trials

A listing of Pain medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,187 clinical trials
K Kaiyan Zhang, M.D.

Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)

To evaluated the safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer.

18 years of age Male Phase 2
S Susan Sharry

XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to determine how well the study drug XL092 is helping to treat a participant's cancer after 16 weeks of treatment. Researchers will also look at how safe the XL092 is and how well the XL092 is working. XL092 is an oral tablet that will …

18 years of age Male Phase 2
H Huojun Zhang, M.D.

Hypofractionated Post-prostatectomy Radiotherapy (HYPORT)for Localized Prostate Cancer

The aim of this trial is to compare the safety outcomes of Hypofractionated postprostatectomy radiotherapy (HYPORT) and Conventionally fractionated postprostatectomy radiotherapy(COPORT) in treating patients with localized prostate cancer. Accumulating evidence has proven the safety and feasibility of HYPORT for localized prostate cancer.But for localized prostate cancer,the optimal dose per fraction …

years of age Male Phase N/A
K Kato Rans, MD

Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer

Evaluation of the impact of metastasis-directed therapy in patients with castration-refractory prostate cancer and a maximum of 5 progressive lesions.

18 years of age Male Phase 3

Magnesium Sulfate as an Adjunctive Analgesic in Prostate Surgery

The purpose of this clinical trial is to determine if receiving magnesium sulfate as an adjunctive analgesic for prostate surgery is effective in reducing pain. Subjects will be randomized to receive magnesium or not receive it, as part of a standardized general anesthetic for prostate surgery. The primary objective is …

18 years of age Male Phase 4
K Kelly Stratton, MD

Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer

Proposed immunotherapy with an extended course of Sipuleucel-T treatment may induce a more robust immune response and improve the anti-cancer efficacy of Sipuleucel-T in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC).

18 years of age Male Phase 1
J Jiarou Wang, MD

177Lu-LNC1011 in Patients With Metastatic Castration-resistant Prostate Cancer

This study employed an open-label, non-randomized design, representing the first human trial of its kind. It utilized a standard 3+3 dose-escalation approach, focusing on patients with metastatic castration-resistant prostate cancer, initiating treatment at a dose of 1.85 GBq over a 6-week period. Subsequent cohorts underwent sequential 50% dose escalations until …

18 - 80 years of age Male Phase N/A
G George Salem, PhD

Golf Recreational Exercise for Enhanced Survivorship in Prostate Cancer Survivors

This clinical trial evaluates a golf recreational exercise program for enhancing survivorship in underrepresented prostate cancer survivors. Golf is a multimodal recreational activity that requires participants to utilize all muscle groups to perform the golf swing, walk over hilly and uneven terrain, maintain balance during putting and squat-like tasks. Physical …

55 - 85 years of age Male Phase N/A
E Erynn Peyton

Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer

The purpose of this study is to evaluate intermittent relugolix + androgen receptor pathway inhibitor (ARPI) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) achieving optimal PSA response.

18 years of age Male Phase 2
M Michal Safarty

Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy

The aim of this study is to assess the progression free survival (PFS) of SABR alone and SABR + 177Lu-prostate-specific membrane antigen (PSMA) in patients with oligometastatic prostate cancer undergoing PSMA positron emission tomography (PET) staging.

18 years of age Male Phase 2

Simplify language using AI